VERASTEM, INC. (VSTM)
Verastem Oncology to Host Investor Conference Call and Report Updated Data and Progress Across VS-7375 Oral KRAS G12D (ON/OFF) Inhibitor TARGET-D Clinical Program
Verastem Oncology to Host Investor Conference Call and Report Updated Data and Progress Across VS-7375 Oral KRAS G12D (ON/OFF) Inhibitor TARGET-D Clinical Program
📈 **POSITIVE** • High confidence analysis (95%) • Strong positive business development • Significant competitive advantage **Sentiment:** Positive (95%) **Content type:** Business